Investor Centre

ASX
LCT 0.024   Last updated EOD 21st June 2018
Fact sheet
The following fact sheets provide a summary of our current business and research pipeline.
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.

Fact sheet

The following fact sheet provides a summary of our current business and research pipeline.

Diatranz Otsuka Limited

Living Cell Technologies formed a partnership with Otsuka Pharmaceutical Factory, Inc. (Otsuka) in 2011 establishing the 50:50 New Zealand joint venture company Diatranz Otsuka Limited (DOL). DOL is a private company incorporated in New Zealand. 

 

LCT sold its 50 percent shareholding in DOL to Otsuka in January 2018. DOL has agreed to license LCT to use DIABECELL in Australia, Argentina and New Zealand once Otsuka has FDA approval for the product that it is developing under licence in USA.

PRINT PAGE print-icon
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.